Business Context and Reporting Period
This Form 8-K filing by Pavmed Inc. (PAVM) covers events occurring on September 10, 2024, and reported on September 16, 2024. The filing addresses the deconsolidation of a significant subsidiary, Lucid Diagnostics Inc. ("Lucid"), changes to the Board of Directors, and a critical notice regarding the company's continued listing status on The Nasdaq Stock Market.
Key Financial Metrics and Liquidity
- Deconsolidation Impact: The company ceased consolidating Lucid's results effective September 10, 2024, due to a loss of control over a majority of voting power, despite retaining ownership of 31,302,444 Lucid shares.
- Stockholders' Equity: Pro forma financial statements indicate that deconsolidation would have increased stockholders' equity by $9.7 million as of June 30, 2024, moving from a deficit of $18.6 million to a deficit of approximately $9.0 million.
- Expected Gain: The company expects to recognize an estimated non-cash gain of approximately $70 million in the third quarter of 2024. This represents the excess of the estimated fair value of its interest in Lucid and receivables over Lucid's carrying value.
- Accounting Treatment: Post-deconsolidation, the interest in Lucid will be accounted for under the measurement alternative of ASC 321 at estimated fair value. The transaction is not classified as discontinued operations.
Material Changes and Listing Status
- Nasdaq Delisting Notice: On September 10, 2024, Pavmed received a staff determination letter from Nasdaq stating that its securities are subject to suspension and delisting. This follows a failure to regain compliance with the minimum market value of listed securities ($35 million) required under Listing Rule 5550(b)(2) by the September 3, 2024 deadline.
- Compliance Strategy: The company intends to request a hearing before a Nasdaq Hearings Panel to stay the delisting. It plans to demonstrate compliance with Listing Rule 5550(b)(1) (minimum stockholders' equity of $2.5 million) via the Lucid deconsolidation or present a plan to regain compliance.
- Board Changes: James L. Cox, M.D., and Joan B. Harvey resigned from the Board. Sundeep Agrawal, M.D., was appointed as a Class B director and received a stock option grant with a fair value of $250,000, plus a monthly consulting fee of $3,333.
Outlook, Risks, and Contingencies
- Delisting Risk: There is no assurance that the company will regain compliance with Nasdaq listing standards or that the Hearings Panel will grant an extension of time.
- Debt Restructuring: The company continues to explore alternatives to increase stockholders' equity, including restructuring existing senior secured convertible debt.
- Forward-Looking Statements: The filing contains forward-looking statements regarding the hearing outcome, compliance plans, and financial impacts, which are subject to substantial risks and uncertainties.
Investor Verification Checklist
- Verify the outcome of the Nasdaq Hearings Panel regarding the delisting determination.
- Confirm the final audited impact of the $70 million non-cash gain on the Q3 2024 earnings report.
- Monitor progress on the restructuring of senior secured convertible debt to further improve equity position.
- Review the pro forma financial statements (Exhibit 99.2) for detailed adjustments related to the Lucid deconsolidation.